-
1
-
-
75949130829
-
Strategies for treating idiopathic pulmonary fibrosis
-
du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010; 9:129-140.
-
(2010)
Nat Rev Drug Discov
, vol.9
, pp. 129-140
-
-
Du Bois, R.M.1
-
2
-
-
84861382039
-
Idiopathic pulmonary fibrosis: Clinically meaningful primary endpoints in phase 3 clinical trials
-
Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012; 185:1044-1048.
-
(2012)
Am J Respir Crit Care Med
, vol.185
, pp. 1044-1048
-
-
Raghu, G.1
Collard, H.R.2
Anstrom, K.J.3
-
3
-
-
84865112235
-
Idiopathic pulmonary fibrosis: Lung function is a clinically meaningful endpoint for phase 3 trials
-
Du Bois RM, Nathan SD, Richeldi L, et al. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase 3 trials. Am J Respir Crit Care Med 2012; 186:712-715.
-
(2012)
Am J Respir Crit Care Med
, vol.186
, pp. 712-715
-
-
Du Bois, R.M.1
Nathan, S.D.2
Richeldi, L.3
-
4
-
-
84875208959
-
Forced vital capacity as a primary endpoint in idiopathic pulmonary fibrosis treatment trials: Making a silk purse from a sow's ear
-
Wells AU. Forced vital capacity as a primary endpoint in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear. Thorax 2013; 68:309-310.
-
(2013)
Thorax
, vol.68
, pp. 309-310
-
-
Wells, A.U.1
-
5
-
-
84898849450
-
Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: Provisional core sets of domains and instruments for use in clinical trials
-
Saketkoo LA, Mittoo S, Huscher D, et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 2014; 69:428-436.
-
(2014)
Thorax
, vol.69
, pp. 428-436
-
-
Saketkoo, L.A.1
Mittoo, S.2
Huscher, D.3
-
6
-
-
79960426037
-
Long-term course and prognosis of idiopathic pulmonary fibrosis in the modern era
-
Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the modern era. Chest 2011; 140:221-229.
-
(2011)
Chest
, vol.140
, pp. 221-229
-
-
Nathan, S.D.1
Shlobin, O.A.2
Weir, N.3
-
7
-
-
77951170794
-
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis
-
Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35:830-836.
-
(2010)
Eur Respir J
, vol.35
, pp. 830-836
-
-
Zappala, C.J.1
Latsi, P.I.2
Nicholson, A.G.3
-
8
-
-
84455168726
-
Forced vital capacity in patients with idiopathic pulmonary fibrosis: Test properties and minimal clinically important difference
-
du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
-
(2011)
Am J Respir Crit Care Med
, vol.184
, pp. 1382-1389
-
-
Du Bois, R.M.1
Weycker, D.2
Albera, C.3
-
9
-
-
84862826491
-
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis
-
Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67:407-411.
-
(2012)
Thorax
, vol.67
, pp. 407-411
-
-
Richeldi, L.1
Ryerson, C.J.2
Lee, J.S.3
-
10
-
-
84901810710
-
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
-
Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071-2082.
-
(2014)
N Engl J Med
, vol.370
, pp. 2071-2082
-
-
Richeldi, L.1
Du Bois, R.M.2
Raghu, G.3
-
11
-
-
20544443765
-
The clinical course of patients with idiopathic pulmonary fibrosis
-
Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142:963-967.
-
(2005)
Ann Intern Med
, vol.142
, pp. 963-967
-
-
Martinez, F.J.1
Safrin, S.2
Weycker, D.3
-
12
-
-
84901759236
-
A phase 3 trial of pirfe-nidone in patients with idiopathic pulmonary fibrosis
-
King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfe-nidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083-2092.
-
(2014)
N Engl J Med
, vol.370
, pp. 2083-2092
-
-
King, T.E.1
Bradford, W.Z.2
Castro-Bernardini, S.3
-
13
-
-
79956341531
-
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomized trials
-
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 2011; 377:1760-1769.
-
(2011)
Lancet
, vol.377
, pp. 1760-1769
-
-
Noble, P.W.1
Albera, C.2
Bradford, W.Z.3
-
14
-
-
84859918517
-
Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumonia
-
Corte TJ, Wort SJ, MacDonald PS, et al. Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumonia. Respirology 2012; 17:674-680.
-
(2012)
Respirology
, vol.17
, pp. 674-680
-
-
Corte, T.J.1
Wort, S.J.2
Macdonald, P.S.3
-
15
-
-
10744229010
-
Prognostic value of desaturation during a 6-min walk test in idiopathic interstitial pneumonia
-
Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-min walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:1084-1090.
-
(2003)
Am J Respir Crit Care Med
, vol.168
, pp. 1084-1090
-
-
Lama, V.N.1
Flaherty, K.R.2
Toews, G.B.3
-
16
-
-
33748688190
-
Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis
-
Lederer DJ, Arcasoy SM, Wilt JS, et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174:659-664.
-
(2006)
Am J Respir Crit Care Med
, vol.174
, pp. 659-664
-
-
Lederer, D.J.1
Arcasoy, S.M.2
Wilt, J.S.3
-
17
-
-
57949084974
-
Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis
-
Caminati A, Bianchi A, Cassandro R, et al. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Res Med 2009; 103:117-123.
-
(2009)
Res Med
, vol.103
, pp. 117-123
-
-
Caminati, A.1
Bianchi, A.2
Cassandro, R.3
-
18
-
-
33747820181
-
The distance saturation product: A novel measure for mortality prediction in idiopathic pulmonary fibrosis
-
Lettieri CJ, Browning RF, Shorr AF, et al. The distance saturation product: a novel measure for mortality prediction in idiopathic pulmonary fibrosis. Respir Med 2006; 100:1734-1741.
-
(2006)
Respir Med
, vol.100
, pp. 1734-1741
-
-
Lettieri, C.J.1
Browning, R.F.2
Shorr, A.F.3
-
19
-
-
79955520497
-
Six-minute-walk test in idiopathic pulmonary fibrosis: Test validation and minimal clinically important difference
-
Du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183:1231-1237.
-
(2011)
Am J Respir Crit Care Med
, vol.183
, pp. 1231-1237
-
-
Du Bois, R.M.1
Weycker, D.2
Albera, C.3
-
20
-
-
76549135612
-
The 6 min walk in idiopathic pulmonary fibrosis: Longitudinal changes and minimum important difference
-
Swigris JJ, Wamboldt FS, Behr J, et al. The 6 min walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010; 65:173-217.
-
(2010)
Thorax
, vol.65
, pp. 173-217
-
-
Swigris, J.J.1
Wamboldt, F.S.2
Behr, J.3
-
21
-
-
70149083664
-
Heart rate recovery after 6-minute walk test predicts survival in patients with idiopathic pulmonary fibrosis
-
Swigris JJ, Swick J, Wamboldt FS, et al. Heart rate recovery after 6-minute walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest 2009; 136:841-848.
-
(2009)
Chest
, vol.136
, pp. 841-848
-
-
Swigris, J.J.1
Swick, J.2
Wamboldt, F.S.3
-
22
-
-
79953279215
-
Heart rate recovery after 6MWT predicts pulmonary hypertension in patients with IPF
-
Swigris JJ, Olson A, Shlobin OA, et al. Heart rate recovery after 6MWT predicts pulmonary hypertension in patients with IPF. Respirology 2011; 16:439-445.
-
(2011)
Respirology
, vol.16
, pp. 439-445
-
-
Swigris, J.J.1
Olson, A.2
Shlobin, O.A.3
-
23
-
-
80052940121
-
Has my patient responded? Interpreting clinical measurements such as the 6-min-walk test
-
Dolmage TE, Hill K, Evans RA, Goldstein RS. Has my patient responded? Interpreting clinical measurements such as the 6-min-walk test. Am J Respir Crit Care Med 2011; 184:642-646.
-
(2011)
Am J Respir Crit Care Med
, vol.184
, pp. 642-646
-
-
Dolmage, T.E.1
Hill, K.2
Evans, R.A.3
Goldstein, R.S.4
-
24
-
-
84880086518
-
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials
-
Collard HR, Yow E, Richeldi L, et al. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res 2013; 14:73.
-
(2013)
Respir Res
, vol.14
, pp. 73
-
-
Collard, H.R.1
Yow, E.2
Richeldi, L.3
-
25
-
-
84863450246
-
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis
-
Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186:88-95.
-
(2012)
Am J Respir Crit Care Med
, vol.186
, pp. 88-95
-
-
Noth, I.1
Anstrom, K.J.2
Calvert, S.B.3
-
26
-
-
84861394764
-
Prednisone, azathioprine and N-acetylcysteine for pulmonary fibrosis
-
The Idiopathic Pulmonary Fibrosis Clinical Research Network
-
The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366:1968-1977.
-
(2012)
N Engl J Med
, vol.366
, pp. 1968-1977
-
-
-
27
-
-
79951844263
-
Clinical course and prediction of survival in idiopathic pulmonaryfibrosis
-
Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonaryfibrosis. Am J Respir Crit Care Med 2011; 183:431-440.
-
(2011)
Am J Respir Crit Care Med
, vol.183
, pp. 431-440
-
-
Ley, B.1
Collard, H.R.2
King, T.E.3
-
28
-
-
84897459884
-
All-cause mortality rate in patients with idiopathic pulmonary fibrosis: Implications for the design and execution of clinical trials
-
King TE Jr, Albera C, Bradford WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis: implications for the design and execution of clinical trials. Am J Respir Crit Care Med 2014; 189:825-831.
-
(2014)
Am J Respir Crit Care Med
, vol.189
, pp. 825-831
-
-
King Jr., T.E.1
Albera, C.2
Bradford, W.Z.3
-
29
-
-
0025248164
-
Clinical deterioration in patients with idiopathic pulmonary fibrosis: Causes and assessment
-
Panos R. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88:396-404.
-
(1990)
Am J Med
, vol.88
, pp. 396-404
-
-
Panos, R.1
-
30
-
-
74549213651
-
Trial and error: How to avoid commonly encountered limitations of published clinical trials
-
Kaul S, Diamond GA. Trial and error: how to avoid commonly encountered limitations of published clinical trials. J Am Coll Cardiol 2010; 55:415-427.
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 415-427
-
-
Kaul, S.1
Diamond, G.A.2
-
31
-
-
83555164738
-
Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide
-
Kim HJ, Brown MS, Elashoff R, et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol 2011; 21:2455-2465.
-
(2011)
Eur Radiol
, vol.21
, pp. 2455-2465
-
-
Kim, H.J.1
Brown, M.S.2
Elashoff, R.3
-
32
-
-
0030886936
-
Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: Correlation with pathologic scoring
-
Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR 1997; 169:977-983.
-
(1997)
AJR
, vol.169
, pp. 977-983
-
-
Kazerooni, E.A.1
Martinez, F.J.2
Flint, A.3
-
33
-
-
84864815252
-
Patient-reported outcomes in idiopathic pulmonary fibrosis research
-
Swigris JJ, Fairclough D. Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest 2012; 142:291-297.
-
(2012)
Chest
, vol.142
, pp. 291-297
-
-
Swigris, J.J.1
Fairclough, D.2
-
34
-
-
77957202563
-
Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire
-
Yorke J, Jones PW, Swigris JJ. Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax 2010; 65:921-926.
-
(2010)
Thorax
, vol.65
, pp. 921-926
-
-
Yorke, J.1
Jones, P.W.2
Swigris, J.J.3
-
35
-
-
77955074501
-
Development of the ATAQ-IPF: A tool to assess quality of life in IPF
-
Swigris JJ, Wilson SR, Green KE, et al. Development of the ATAQ-IPF: a tool to assess quality of life in IPF. Health Qual Life Outcomes 2010; 8:77.
-
(2010)
Health Qual Life Outcomes
, vol.8
, pp. 77
-
-
Swigris, J.J.1
Wilson, S.R.2
Green, K.E.3
-
36
-
-
64749097794
-
Serum albumen concentration and waiting list mortality in idiopathic interstitial pneumonia
-
Zisman DA, Kawut SM, Lederer DJ, et al. Serum albumen concentration and waiting list mortality in idiopathic interstitial pneumonia. Chest 2009; 135:929-935.
-
(2009)
Chest
, vol.135
, pp. 929-935
-
-
Zisman, D.A.1
Kawut, S.M.2
Lederer, D.J.3
-
37
-
-
33644828168
-
Prognostic value of circulating kl-6 in idiopathic pulmonary fibrosis
-
Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating kl-6 in idiopathic pulmonary fibrosis. Respirology 2006; 11:164-168.
-
(2006)
Respirology
, vol.11
, pp. 164-168
-
-
Yokoyama, A.1
Kondo, K.2
Nakajima, M.3
-
38
-
-
63849228099
-
Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis
-
Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009; 135:1557-1563.
-
(2009)
Chest
, vol.135
, pp. 1557-1563
-
-
Kinder, B.W.1
Brown, K.K.2
McCormack, F.X.3
-
39
-
-
84855264195
-
Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis
-
Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185:67-76.
-
(2012)
Am J Respir Crit Care Med
, vol.185
, pp. 67-76
-
-
Richards, T.J.1
Kaminski, N.2
Baribaud, F.3
-
40
-
-
84878585570
-
The red cell distribution width as a prognostic indicator in IPF
-
Nathan SD, Reffett T, Brown AW, et al. The red cell distribution width as a prognostic indicator in IPF. Chest 2013; 143:1692-1698.
-
(2013)
Chest
, vol.143
, pp. 1692-1698
-
-
Nathan, S.D.1
Reffett, T.2
Brown, A.W.3
-
41
-
-
58249092608
-
Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis
-
Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Res Med 2009; 103:180-186.
-
(2009)
Res Med
, vol.103
, pp. 180-186
-
-
Song, J.W.1
Song, J.K.2
Kim, D.S.3
-
42
-
-
33645297106
-
Brain natruiretic peptide is a prognostic parameter in chronic lung disease
-
Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natruiretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006; 173:744-750.
-
(2006)
Am J Respir Crit Care Med
, vol.173
, pp. 744-750
-
-
Leuchte, H.H.1
Baumgartner, R.A.2
Nounou, M.E.3
-
43
-
-
77957852320
-
Elevated brain natriuretic peptide predicts mortality in interstitial lung disease
-
Corte TJ, Wort SJ, Gatzoulis MA, et al. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J 2010; 36:819-825.
-
(2010)
Eur Respir J
, vol.36
, pp. 819-825
-
-
Corte, T.J.1
Wort, S.J.2
Gatzoulis, M.A.3
-
44
-
-
84881669432
-
ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias
-
Travis WD, Costabel U, Hansell DM, et al. ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188:733-748.
-
(2013)
Am J Respir Crit Care Med
, vol.188
, pp. 733-748
-
-
Travis, W.D.1
Costabel, U.2
Hansell, D.M.3
-
46
-
-
84855264195
-
Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis
-
Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185:67-76.
-
(2012)
Am J Respir Crit Care Med
, vol.185
, pp. 67-76
-
-
Richards, T.J.1
Kaminski, N.2
Baribaud, F.3
-
47
-
-
84885467568
-
Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis
-
Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 2013; 5:205ra136.
-
(2013)
Sci Transl Med
, vol.5
-
-
Herazo-Maya, J.D.1
Noth, I.2
Duncan, S.R.3
-
48
-
-
34247618238
-
Idiopathic pulmonary fibrosis and pul monary hypertension: Connecting the dots
-
Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pul monary hypertension: connecting the dots. Am J Respir Crit Care Med 2007; 175:875-880.
-
(2007)
Am J Respir Crit Care Med
, vol.175
, pp. 875-880
-
-
Nathan, S.D.1
Noble, P.W.2
Tuder, R.M.3
|